uniQure shared news today that the first European patients were dosed in their open-label study of AMT-130, a huntingtin-lowering gene therapy. Safety data from the first group of 10 participants in the USA is expected in the second quarter of 2022.
uniQure shared news today that the first European patients were dosed in their open-label study of AMT-130, a huntingtin-lowering gene therapy. Safety data from the first group of 10 participants in the USA is expected in the second quarter of 2022.
